- In late May 2026, activist investor Ancora Holdings publicly urged H.B. Fuller to drop its pursuit of British medical supplier Advanced Medical Solutions Group and instead undertake a full strategic review following reported acquisition interest in the adhesives maker.
- Ancora’s campaign spotlights concerns about higher leverage, valuation pressure, and management’s ability to integrate complex cross-border deals, putting H.B. Fuller’s capital allocation priorities under sharper scrutiny.
- We’ll now examine how Ancora’s call for a strategic review and opposition to the Advanced Medical Solutions deal could reshape H.B. Fuller’s investment narrative.
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
H.B. Fuller Investment Narrative Recap
To own H.B. Fuller, you need to believe in its ability to compound value through disciplined capital allocation in adhesives and adjacent specialties, while managing leverage and end market softness. Ancora’s pushback on the Advanced Medical Solutions bid directly targets that capital allocation story and could influence the key near term catalyst, which is how management balances growth initiatives with the already elevated net debt to EBITDA profile.
The most relevant backdrop to this activism is Fuller’s recent decision to raise its FY2026 outlook to mid single digit net revenue growth, following Q1 2026 results that showed higher earnings on slightly lower sales. That guidance makes Ancora’s focus on leverage, deal risk and valuation all the more important to watch, because any shift in acquisition plans or a possible strategic review could change how investors assess those same growth targets.
Yet even with improving earnings and higher guidance, investors should be aware that Fuller’s elevated net debt to EBITDA ratio could become a pressure point if...
Read the full narrative on H.B. Fuller (it's free!)
H.B. Fuller's narrative projects $3.9 billion revenue and $243.6 million earnings by 2029. This requires 4.5% yearly revenue growth and about an $83.8 million earnings increase from $159.8 million today.
Uncover how H.B. Fuller's forecasts yield a $70.43 fair value, a 17% upside to its current price.
Exploring Other Perspectives
Simply Wall St Community members currently see fair value between US$59.55 and US$70.43 across 2 independent views, underlining how far opinions can spread. Set that against the concern about higher leverage if an AMS style deal proceeded, and you can see why many readers may want to compare several scenarios before deciding what H.B. Fuller’s future could look like.
Explore 2 other fair value estimates on H.B. Fuller - why the stock might be worth as much as 17% more than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your H.B. Fuller research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free H.B. Fuller research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate H.B. Fuller's overall financial health at a glance.
Curious About Other Options?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com